Michael Bowen is an NHMRC Peter Doherty Biomedical Fellow in the Psychopharmacology Laboratory in the School of Psychology at the University of Sydney. Michael's research focuses on developing novel drug treatments for mental and neurological disorders, such as addiction, autism, and epilepsy. In particular, he focuses on developing oxytocin-based treatments and drug treatments that target the extrasynaptic GABA-A receptor system. To facilitate the development of these new treatments, he also conducts extensive research aimed at gaining a better understanding of the neurobiological, genetic, epigenetic, and pharmacological abnormalities that underlie these disorders.